1.
Mohr B, Oelschlaegel U, Thiede C, Stewart MM, Ehninger G, Platzbecker U. The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells. Haematologica [Internet]. 2009Feb.27 [cited 2026Nov.16];94(3):430-1. Available from: https://haematologica.org/article/view/5198